Evidence mapPaperPMID 41940580Full record

ArticleBlood2026

Platelet Drp1 phosphorylation provides a platform for immune-based platelet function testing.

David A Barrios, Shihui Guo, Matthew Powers, Secil Koseoglu, Sabrina Zerbey, Roosevelt Lu, Alexander Cermak, Caroline Vayne, Somal Khan, Omozuanvbo Aisiku and 5 more

Abstract read
In one paragraph

Article in Blood, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

David A BarriosDivision of Hemostasis and Thrombosis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Shihui GuoDivision of Hemostasis and Thrombosis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.ORCID 0000-0002-0542-1221
Matthew PowersPlateletDiagnostics, LLC, Watertown, MA.ORCID 0009-0000-4005-6779
Secil KoseogluDivision of Hemostasis and Thrombosis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Sabrina ZerbeyCancer Clinical Trials Office, Beth Israel Deaconess Medical Center, Boston, MA.
Roosevelt LuCancer Clinical Trials Office, Beth Israel Deaconess Medical Center, Boston, MA.
Alexander CermakCancer Clinical Trials Office, Beth Israel Deaconess Medical Center, Boston, MA.
Caroline VayneDepartment of Haemostasis, Regional University Hospital Centre Tours, Tours, France.ORCID 0000-0002-7106-4365
Somal KhanDivision of Hemostasis and Thrombosis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Omozuanvbo AisikuPlateletDiagnostics, LLC, Watertown, MA.
Arielle UrmanCancer Clinical Trials Office, Beth Israel Deaconess Medical Center, Boston, MA.ORCID 0000-0001-9903-7548
Joseph ThomasCancer Clinical Trials Office, Beth Israel Deaconess Medical Center, Boston, MA.
Rushad PatellDivision of Hemostasis and Thrombosis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.ORCID 0000-0002-8426-3398
Jeffrey I ZwickerHematology Service, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-5810-6893
Robert FlaumenhaftDivision of Hemostasis and Thrombosis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.

Funding

The Patient-Reported Outcomes, Community-Engagement and Language (PRO-CEL) CoreP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · 1985 to 2025
$88.4M
NCI NIH HHS P30 CA008748NHLBI NIH HHS U54 HL119145
6 · The paper itself

Abstract

abstractDynamin-related protein 1 (Drp1) is an abundant platelet protein best known for its function in mitochondrial fission. However, little is known about how Drp1 is controlled during platelet activation. While evaluating signaling pathways leading to phosphorylation of Drp1 in platelets, we identified a phosphorylation network wherein activation of G protein-coupled receptors or immunoreceptor tyrosine-based activation motif (ITAM)/hemITAM receptors resulted in phosphorylation of Ser616-Drp1 via p38. These signaling mechanisms were reinforced by ADP- and thromboxane A2 (TxA2)-mediated amplification pathways. In contrast, exposure of platelets to pacifying agents such as prostaglandin E1 or nitric oxide resulted in Ser637-Drp1 phosphorylation by cyclic nucleotide-dependent protein kinases. This unique circuitry was leveraged to develop immune-based platelet function assays, enabling enzyme-linked immunosorbent assay and lateral flow assay formats. Compared with standard platelet function assays, Drp1 phosphorylation remained robust in whole blood samples following agitation or extended incubation, and samples could be frozen for batching. As proof of principle for antiplatelet testing, phospho-Drp1 measurements were obtained at baseline, during a week of aspirin or clopidogrel exposure, and during a week of washout. Arachidonic acid-induced Ser616-Drp1 phosphorylation following aspirin ingestion demonstrated an enhanced dynamic range with improved linearity relative to light transmission aggregometry and an improved signal-to-noise ratio relative to the VerifyNow aspirin test. Ser637-Drp1 phosphorylation enabled sensitive detection of clopidogrel ingestion. These studies elucidate the unique signaling circuit controlling Drp1 phosphorylation in platelets and validate the approach of using detailed knowledge of platelet signaling pathways to develop high-fidelity immune-based assays to monitor platelet function.

Indexed as

Blood PlateletsDynaminsPlatelet Function TestsAspirinHumansPhosphorylationPlatelet ActivationPlatelet Aggregation InhibitorsSignal TransductionThromboxane A2AspirinDNM1L protein, humanDynaminsPlatelet Aggregation InhibitorsThromboxane A2

Identifiers

PMID41940580
PMCPMC13138731

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.